Identification of Trombospondin-1 as a Novel Amelogenin Interactor by Functional Proteomics

Angela Capolupo¹,², Chiara Cassiano¹, Agostino Casapullo¹, Giuseppina Andreotti³, Maria V. Cubellis⁴, Andrea Riccio⁵, Raffaele Riccio¹* and Maria C. Monti¹*

¹ Department of Pharmacy, University of Salerno, Salerno, Italy, ² PhD Program in Drug Discovery and Development, University of Salerno, Salerno, Italy, ³ Istituto di Chimica Biomolecolare, Consiglio Nazionale Delle Ricerche (CNR), Napoli, Italy, ⁴ Department of Biology, University of Naples Federico II, Napoli, Italy, ⁵ Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, Caserta, Italy

Amelogenins are a set of low molecular-weight enamel proteins belonging to a group of extracellular matrix (ECM) proteins with a key role in tooth enamel development and in other regeneration processes, such as wound healing and angiogenesis. Since only few data are actually available to unravel amelogenin mechanism of action in chronic skin healing restoration, we moved to the full characterization of the human amelogenin isoform 2 interactome in the secretome and lysate of Human Umbilical Vein Endothelial cells (HUVEC), using a functional proteomic approach. Trombospondin-1 has been identified as a novel and interesting partner of human amelogenin isoform 2 and their direct binding has been validated through biophysical orthogonal approaches.

Keywords: functional proteomics, protein-protein interaction, amelogenin, thrombospondin-1, extracellular matrix proteins, wound healing

INTRODUCTION

Amelogenins are a set of low molecular-weight enamel matrix proteins belonging to a group of extracellular matrix (ECM) proteins whose genes are greatly preserved, with a key role in tooth enamel advance (Deutsch, 1989; Moradian-Oldak, 2001; Grandin et al., 2012). Amelogenin gene is conserved across vertebrate species, mainly in the N- and C-terminal regions. There are two amelogenin genes (AMELX and AMELY) located on the X and Y chromosomes, respectively. The coding sequence of AMELX had 95.1% identity to that of AMELY (Delgado et al., 2005). The heterogeneity of amelogenins in terms of molecular size and amino acid composition is an outcome of the extended population of their related mRNAs, produced by alternative splicing and translated into a broad mixture of nascent proteins and peptides, among which the most abundant species are the isoforms I and II differing only at the 19–34 peptide level (Svensson Bonde and Bülow, 2012). Amelogenins show a hydrophobic amino terminal fragment and a hydrophilic carboxyl-terminal one, conferring them bipolar properties; moreover, the prevalence of proline, glutamine, leucine, and histidine residues in their aminoacidic composition drives amelogenins to a self-assembling process into large hydrophobic aggregates, which seems to be one of the mechanism engaged in periodontal or tissue regeneration (Khan et al., 2012; Yoshimi et al., 2016). The solubility varies depending on temperature and pH and it is low at neutral pH. Under these conditions, amelogenin species aggregate into larger arrangements, up to form a sort of platelets resembling a stable extra cellular matrix and this transitory complex supplies adhesion sites for cells to connect themselves (Bonde and Bülow, 2012).
In literature two main functions of amelogenins are well-documented: their role in dental enamel formation and their involvement in regeneration processes (Grandin et al., 2012). Amelogenins are mainly involved in dental enamel formation and tooth repair playing an important role in enamel crystal edification, direction, and maturation during crown formation and, thus, they serve as a regulator of enamel biomineralization, endorsing renewal of the periodontium (Grandin et al., 2012). On the contrary, mutations of the human AMELX gene lead to X-linked amelogenesis imperfecta (AI), an inborn disease affecting the tooth development in primary and permanent dentition (Sasaki and Shimokawa, 1995). On this basis, amelogenins are currently considered a relevant adjutants in the treatment of periodontal defects and they are the main components of the enamel matrix derivative Emdogain® (Emdogain, Straumann), a gel preparation protecting tooth and promoting the regeneration of hard and soft tissues in periodontitis (Sculean et al., 2007).

Besides, based on the pharmacological ability of amelogenins in the successful healing of oral wounds, several studies focused the attention on their potential role in other regeneration processes, such as skin wound healing and angiogenesis (Hoang et al., 2000). Indeed, several studies have shown the helpful role of amelogenins on wound healing and tissue regeneration, activating several crucial cell reactions for tissue restoration and healing, such as proliferation, migration, adhesion and differentiation (Vowden et al., 2006). A care product Xelma® (Xelma, Mönlycke Health Care) containing amelogenins has been marketed and used in treatment of chronic wounds (Romanelli et al., 2008a,b). Furthermore, periodontal ligament cells (PDL) have been treated with amelogenins for monitoring their effects on cell recruitment, proliferation, and differentiation, indicating an amelogenin-mediated proliferation. This role together with enhanced migration of cells points toward a beneficial wound-healing effects observed for PDL cells stimulated by amelogenins in vitro (Davenport et al., 2003). Moreover, a higher proliferation of gingival and dermal fibroblasts following treatment with amelogenins has also been observed (Weinberg et al., 2010). Finally, amelogenins seemed to encourage the angiogenic activity of HUVEC and HMVEC cells stimulating their proliferation and migration also by upregulating mRNA expression of the angiogenic factor ANG-2 and adhesion molecules ICAM-1 (Bertl et al., 2009).

In order to increase the knowledge on these regeneration processes, Fukuda and co-workers developed and published a functional proteomic analysis of the amelogenins biological partners. They identified several cytoskeletal proteins and chaperones of heat shock protein 70 (HSP70) family in SaOS-2 osteoblastic cell lysates, as amelogenins partners. Moreover, the proteomic outlines of amelogenin-partners in the membrane fraction of the cell extracts revealed the endoplasmic reticulum (ER)-associated proteins as its best targets, such as glucose-regulated protein 78 (Fukuda et al., 2013).

Since no data are available to unravel amelogenin mechanism of action in chronic skin healing restoration at molecular level, we moved to the full characterization of the interactome of AMELX isomorf II, here called AMEL-2, in the secretome and lysate of human umbilical vein endothelial cells (HUVEC), chosen as an appropriate in vitro model, using a functional proteomic strategy. Functional proteomics is a multi-faced strategy useful to characterize proteins interactions and it has gaining increasing interest to define the “targetome” of macromolecules to elucidate their activity through the affinity with their partners, forming transient and/or stable complexes which in turn mediate biological responses (Raida, 2011). Our best approach is based on the “in solution pull-down” strategy, in which the macromolecule is used as a bait to fish out its specific partners among a complex mixtures, then identified by tandem MS and bioinformatics (Margarucci et al., 2015). Here, we have identified several AMEL-2 potential targets and, among them, we pointed out thrombospondin-1 (TSP-1) as its novel and interesting partner validating the direct binding between the counterparts thought orthogonal biophysical approaches.

MATERIALS AND METHODS

Cell Culture and Secretome

HUVEC cells were grown in plates using EGM2 with 1% (v/v) growth factors (hFGF, VEGF, R3-IGF-1), hydrocortisone, ascorbic acid, glutamine and heparin, keeping them incubated at 37°C in a 5% CO2 atmosphere and collected in the first phase of the cell cycle (G1). The cells were harvested by centrifugation (600 g, 5 min), washed twice with PBS (NaH2PO4 50 mM and NaCl 150 mM, pH 7.4) and resuspended in 450 µl of PBS at 0.1% of Igepal together with 50 µl of protease inhibitor cocktail (AESBF (4- (2-Aminophenylbenzenesulfonyl fluoride hydrochloride), aprotinin, bovine hydrogen chloride, E-64 [N- (trans-epoxy succinyl) -L-leucine, 4-guanidobutyramide, EDTA, salt of leupeptine bisulfate] to avoid protein degradation. The resuspended pellet was subjected to homogenization by a manual "Dounce" homogenizer and centrifuged at 10,000 rpm for 5 min at 4°C (Centrifuge 5424-R, Eppendorf). Protein-rich supernatant was extracted and thus separated from insoluble pellets, consisting of membranes and cytoplasmic organelles. The concentration of protein lysate was estimated by Bradford assay and diluted to obtain a concentration of 1 mg/ml (Bradford, 1976).

The secretome was harvested from the cultured cells and concentrated using an Amicon membrane (Millipore); protein concentration was evaluated by Bradford’s assay to obtain a final value of 6 mg/ml.

Cloning, Expression, and Purification of Recombinant AMEL-2

AMEL-2 was a kind gift of Prof Leif Bülow (Department of Pure and Applied Biochemistry, Lund University, Lund, Sweden) and it was expressed and purified according to the protocol outlined by Svensson Bonde and Bülow (2012).

MALDI-TOF Analysis

AMEL-2 sample at a concentration of 12.5 nM (1 µl) was mixed on the spot of the MALDI plate with 1 µl of the saturated CHCA matrix solution (Sigma Aldrich) in 50% ACN, 50% H2O, 0.1% TFA and subjected to mass-spectrometric analysis using MALDI-TOF (MALDI micro MX, Waters) to verify its molecular weight.
MALDI analysis was conducted in linear mode, with laser values ranging from 250 to 280 arbitrary units. As calibrant, a mixture of lysozyme and albumin from bovine serum was used.

**Peptide Mapping of AMEL-2**

One microgram of AMEL-2 were incubated in AMBIC 50 mM with 10 ng of Tryp / Lys-C (1:100) (Promega) in AMBIC (NH₄HCO₃) 50 mM at 37°C for 4 h. The peptide mixture obtained by proteolytic digestion was measured by MALDI-TOF (MALDI micro MX, Waters) using saturated CHCA matrix solution (Sigma Aldrich) in 50% ACN, 50% H₂O, 0.1% TFA. 1 μL of the peptide mixture was mixed with 1 μL of matrix on the spot of the sample holder plate. Mass spectra were acquired in positive linear or reflectron mode.

**Biotinylation of AMEL-2 Functional Groups**

Five micromolar of AMEL-2 and 75 μM biotin (Thermo Scientific) were incubated in NaHCO₃ 0.05% acetic acid. The concentration and purification steps of the sample holder plate. Mass spectra were acquired in positive linear or reflectron mode.

**Peptide Mapping of AMEL-2**

One microgram of AMEL-2 were incubated in AMBIC 50 mM with 10 ng of Tryp / Lys-C (1:100) (Promega) in AMBIC (NH₄HCO₃) 50 mM at 37°C for 4 h. The peptide mixture obtained by proteolytic digestion was measured by MALDI-TOF (MALDI micro MX, Waters) using saturated CHCA matrix solution (Sigma Aldrich) in 50% ACN, 50% H₂O, 0.1% TFA. 1 μL of the peptide mixture was mixed with 1 μL of matrix on the spot of the sample holder plate. Mass spectra were acquired in positive linear or reflectron mode.

**Combination of Affinity Chromatography and Proteomic Analysis**

AMEL-2-biotin adduct (1 or 3 nmol) and the control linker were distinctly incubated with 1 mg of HUVEC cells lysate or secretome, under continuous shaking (1 h, 4°C) and then, 20 μL of streptavidin modified beads (Pierce) were added and left for 1 h at 4°C. The beads were centrifuged (865 g, 1 min, 4°C) and rinsed six times with PBS (pH 7.4). The proteins interacting with AMEL were eluted by adding 35 μL of Laemmly buffer for 30 min at 30°C, separated on 12% SDS-PAGE and stained with Coomassie G-250 (Bio-Rad, Hercules, CA). SDS-PAGE gel lanes were divided in several pieces and digested. The procedure has been done twice with opportune controls as the matrix bearing the linker without any protein and the sole EGM2. Each gel piece was rinsed with water and CH₃CN and exposed to in situ breakdown as described by Shevchenko et al. (2006). Concisely, each gel piece was treated with 10 mM 1,4-dithiothreitol (DTT) and then with 54 mM iodoacetamide, rinsed and rehydrated in trypsin solution (12 ng/mL) on ice for 1 h. Following AMBIC treatment (30 μL, 50 mM, pH 7.5), protein breakdown was carried out overnight at 37°C. The solution was gathered and peptides were extracted from the gel pieces using 100% CH₃CN. The peptide sample was dehydrated and suspended in formic acid (FA, 10%) before MS analysis. The peptide mixture (5 μL) was introduced in a nano-ACQUITY UPLC system (Waters). Peptides were separated on a 1.7 mm BEH C18 column (Waters) at a flow rate of 400 nL/min. Peptide elution was achieved with a linear gradient (solution A: 95% H₂O, 5% CH₃CN, 0.1% FA; solution B: 95% CH₃CN, 5% H₂O, 0.1% FA); 15–50% B over 55 min). MS and MS/MS data were acquired on a LTQ XL mass spectrometry system (ThermoScientific). The five most intense doubly and triply charged ions were broken. The MS results were treated by MS Converter software to obtain the peak lists for protein identification. Database searches were performed on the Mascot server (http://www.matrixscience.com/). The SwissProt database was employed [settings: trypsin with possible two missed cleavages; carboxymethyl (C) as fixed modification and oxidation (M) and phosphorylation (ST); peptide tolerance 80 ppm; MS/MS tolerance 0.8 Da].

**STRING Analysis**

String analysis (Search Tool for the Retrieval of Interacting Genes/Proteins, http://string.embl.de/) have been carried out using STRING-10 server to predict the protein-protein interaction (Sharma et al., 2016a,b; Sharma and Bisht, 2017a,b) of AMEL targets. STRING database employs a mixture of prediction approaches and an combination of experimental data (neighborhood, gene fusion, co-expression, experiments, databases, text mining, co-occurrence). Network was completed at 0.4 confidence level.

**Validation of the Interaction between AMEL-2 and TSP-1 by Western Blotting and Surface Plasmon Resonance**

Proteins eluted from the above-described experiments were separated on 12% SDS-PAGE and moved to a nitrocellulose membrane. The membrane was put for 1 h in a blocking solution made by 25 mM Tris pH 8, 125 mM NaCl, 0.05% Tween-0, 5% non-fat dried milk, primary antibodies raised against TSP-1 (1:500; Novus Biologicals). The recognition of specific epitopes was favorite overnight, at 4°C. Then, membrane was put for 1 h with an anti-rabbit peroxidase-conjugated secondary antibody (1:5,000) (Sigma-Aldrich). TSP-1 was detected by a chemoluminescence detection system. AMEL-2 was immobilized onto a Biacore 3,000 (GE Healthcare) using a CM5 sensor chip using standard amine coupling procedures. Phosphate–buffered saline (10 mM Na₂HPO₄ and 150 mM NaCl, pH 7.4) was the running buffer. The carboxymethyl dextran surface was activated as reported by the GE Healthcare protocol and AMEL-2 was diluted to a final concentration from 50 nM and injected at flow rate of 5 μL/min. After several injections, a RU of 10,000 was measured. The activated carboxymethyl dextran surface was finally blocked with a 7-min injection of 1.0 M ethanolamine-HCl, pH 8.5, at 5 μL/min. TSP-1 solutions (Abnova; from 50 nM to 1 μM) or alternative BSA and lysozime as negative controls, were prepared in running buffer and injected. Since the binding curve went back to baseline in a reasonable time, no regeneration process was mandatory. The experiments were done at a flow rate of 10 μL/min, using a 3 min injection time. The dissociation time was set at 600 s. Rate constants for associations (ka) dissociations (kd) and the dissociation constants (Kd) were calculated by using results from injections of all concentrations, using the BIAevaluation software and the 1:1 Langmuir binding model.
RESULTS

Our process to disclose AMEL-2 action targets has been planned in the next steps: (a) Production of AMEL-2 biotin-tagged specie, (b) Incubation and recovery of its specific partners and identification of the interactome by mass spectrometry and bioinformatics, c) Corroboration of AMEL-2 interactions by bio-orthogonal in vitro assays.

Protein Expression, Purification, and Characterization

A fraction of the expressed AMEL-2 (Figure 1A for sequence, UNIPROT code Q99217, see isoform 2) was measured by MALDI-MS giving a MW of around 19,800 Da, compatible with the isoform II. Protein analysis was performed by digestion with trypsin and MALDI analysis, and three protein fragments were measured and recognized as the 1-24 and 25-168 and 25-170 residues (Supplementary Figure S1), covering almost the entire sequence of AMEL-2.

Generation of Mono-Biotinylated AMEL-2

As a first step, AMEL-2 was treated with a N-hydroxysuccinimide activated S-S biotin linker, providing the AMEL-2-biotin derivative reported in Figure 1B. The reaction was monitored by MALDI-MS and tuned with different molar ratios of the reagents and incubation time, with the best results with a molar excess of biotin of 20 times over AMEL-2 (AMEL-2:biotin 1:20) and 15 min of incubation at room temperature. A mono-modified AMEL-2 species was recovered together with the unreacted species (Figure 1C), following separated from the biotin excess by filtration on a 5 kDa membrane tube, without sample loss (Supplementary Figure S2).

Affinity Chromatography and Mass Spectrometry

Samples of HUVEC protein extracts and the corresponding secretomes were separately incubated with the biotinylated AMEL-2 (1 and 3 nmol, respectively) to endorse the interaction among the protein and its potential target(s) in solution. As control experiments, a sample of the biotin linker modified secretome of the HUVEC cells. As clearly reported in both the interactome fished out by AMEL-2 on the lysate and the secretome (Figure 1A), a few proteins were identified as associated. First of all, actually no interactions of AMEL-2 were treated with streptavidin-bearing matrix beads to recover, a strong band was evident on the gel lanes corresponding to the experiment with the biotinylated AMEL-2, while no signal was detected in the control lanes. Then, surface plasmon resonance was used for corroborating proteomic data and to give evidence of a direct interaction between AMEL-2 and TSP-1, measuring their binding affinity, while bovine serum albumin and lysozyme were used as negative controls (Supplementary Figure S3) AMEL-2 was immobilized on a CM-5 sensor chip prior to the injection of TSP-1 at different concentrations (from 50 to 5,000 nM, Figure 4). Sensorgram analysis gave a dissociation constant (K_D) of the AMEL-2-TSP-1 complex as 878 (±125) nM, while no binding was observed for BSA and lysozyme.

DISCUSSION

Matricellular proteins are extracellular biomolecules acting through their multiple connection to different ligands (Hugo et al., 1995): this is the key feature of these proteins, elucidating their typical variety of functions. These interactions can take concurrently place having various effects on the receptor/ligand equilibrium having different downstream signals, such as the activation of receptors, the arrangement of macro
complexes, inhibition of growth factors, change of protein localization and so on (Resovi et al., 2014). In this scenario, a complete mapping of the amelogenin interactome is required to elucidate its functional role. In addition, the identification of new ligands and protein-protein networks might shed light on its mechanism of action and/or point to new roles for amelogenin in physiological and pathological processes. Amelogenin partners were well-characterized in osteoblast activation by coupling affinity chromatography with proteomics in fractionated SaOS-2 osteoblastic cell lysate (Fukuda et al., 2013). In the cytoplasm, the amelogenin interacting proteins were mainly cytoskeletal and heat shock proteins as heat shock protein 70 (HSP70) whereas in the membrane fraction were mainly endoplasmic reticulum (ER)-associated proteins, such as glucose-regulated protein 78 (Grp78/Bip). These data were promising for understanding the cellular and molecular bases of amelogenin mechanisms in periodontal tissue regeneration.

On the contrary, looking at amelogenin task in chronic skin healing reinstatement, no data were available to unravel its mechanism of action. In this study, the HUVEC cells were used as an opportune model of healing restoration and AMEL-2 partners were disclosed both in the cell lysates and in secretomes through a functional proteomic approach. Several proteins were pulled-down and identified in the cell lysates as potential AMEL-2 targets, mainly cytoskeletal proteins, such as tubulins, myosin and filamin, that were expected on the basis of previous studies (Fukuda et al., 2013).

These cytoskeletal proteins are strictly connected giving a network of protein-protein interaction (PPI see Figure 3) as
TABLE 1 | List of AMEL-2 partners found in both HUVEC cell lysate (upper Table) and HUVEC cell secretome (lower Table).

| Accession | Score | Mass   | Matches | Pep(sig) | Sequences | Seq(sig) | emPAI | Description                  |
|-----------|-------|--------|---------|----------|-----------|----------|-------|------------------------------|
| TBB5_HUMAN | 706   | 50,095 | 48      | 29       | 24        | 18       | 6.22  | Tubulin beta chain           |
| TBB4B_HUMAN | 659   | 50,255 | 41      | 27       | 23        | 19       | 6.16  | Tubulin beta-4B chain        |
| FLNB_HUMAN | 357   | 280,157| 49      | 18       | 48        | 18       | 0.36  | Fila-nin-B                   |
| TBB6_HUMAN | 279   | 50,281 | 21      | 16       | 15        | 13       | 2.72  | Tubulin beta-6 chain         |
| MYH9_HUMAN | 243   | 227,646| 39      | 14       | 36        | 13       | 0.31  | Myosin-9                     |
| FAS_HUMAN  | 188   | 275,877| 31      | 13       | 31        | 13       | 0.25  | Fatty acid synthase           |
| ENOA_HUMAN | 186   | 47,481 | 12      | 7        | 11        | 7        | 1.00  | Alpha-enzyme                 |
| ATPB_HUMAN | 145   | 56,525 | 14      | 8        | 13        | 8        | 0.95  | ATP synthase subunit beta     |
| EF2_HUMAN  | 134   | 96,246 | 22      | 8        | 21        | 8        | 0.48  | Elongation factor 2           |
| RACK1_HUMAN | 89    | 35,511 | 11      | 7        | 9         | 6        | 1.21  | Guanine nucleotide-binding    |
|            |       |        |         |          |           |          |       | protein subunit beta-2-like 1|
| PDIA1_HUMAN | 89    | 57,480 | 14      | 4        | 14        | 4        | 0.39  | Protein disulfide-isomerase   |
| PRDX1_HUMAN | 87    | 22,324 | 13      | 6        | 12        | 6        | 0.52  | Peroxiredoxin-1              |
| TSP1_HUMAN | 46    | 133,291| 7       | 2        | 7         | 2        | 0.07  | Thrombospondin-1             |
| FINC_HUMAN | 495   | 266,052| 47      | 19       | 46        | 19       | 0.40  | Fibronectin                   |
| TSP1_HUMAN | 200   | 133,291| 18      | 10       | 16        | 10       | 0.43  | Thrombospondin-1             |

For each protein, the following parameters are reported: Mascot score (Score), molecular weight (mass), number of matched peptides (Matches) and unique peptides used in the identification process [Match(sig)], number of sequences (Sequences) and the number of significant distinct sequence matches in the protein identification process [Seq(sig)] and the relative quantization of each protein (emPAI).

FIGURE 3 | STRING analysis carried out on the putative AMEL-2 partners identified by proteomics both in HUVEC lysates (A) and secretome (B) revealing protein-protein interaction.

also suggested by STRING interactome analysis and they could be involved into the wound healing process modulating cell locomotion, crucial for repair of injury and for immune response.

Actin polymerization represents a central node for the formation of protrusive structures that drive cell mobility (Ridley et al., 2003). Actin dynamics is an orchestrated cascade of biochemical events that involves a number of regulatory signals and several actin-binding proteins (Lambrechts et al., 2004). Besides, myosin motor proteins play a pivotal role in cells spreading since actin/myosin stress fibers generate the contractile forces that allow the detachment of the rear of the moving cell and, in turn, cell translocation (Lauffenburger and Horwitz, 1996). Specific roles of different myosin isoforms have been reported. In particular, Myosin 9, also called Myosin IIA which targets AMEL-2, is involved in cytoskeleton reorganization, focal contacts formation and lamellipodial retraction negatively affecting cell migration and regulating microtubule dynamics, maintaining a balance between the actomyosin and microtubules. Furthermore, Myosin IIA depletion from human cancer cells resulted in an increased rate of wound closure (Even-Ram et al., 2007). Filamins function as scaffold proteins connecting actin filaments to various cell membrane constituents. Both Filamin A and Filamin B are enriched in focal adhesion which mechanically and biochemically links actin bundles to the ECM acting on cell migration (Tosse et al., 2001). The interaction of AMEL-2 with protein belonging to the tubulin family may also play a role in wound healing. Although the exact mechanism of tubulin action in this process remains debated, the microtubules dynamics...
regulates many aspects of cell migration (Ganguly et al., 2012; Charafeddine et al., 2016).

AMEL-2 is postulated to interact also with Protein disulfide-isomerase (PDIA-1) in the present work. PDI is a member of the thioredoxin superfamily mainly localized in endoplasmic reticulum, where it ensures proper disulfide bond formation in newly synthesized proteins and endowed with three catalytic activities including, thiol-disulfide oxidoreductase, disulfide isomerase and redox-dependent chaperone (Ali Khan and Mutus, 2008). PDI was also found to localize on the surface of platelets, endothelial cells, and leukocytes and to be released into the extracellular environment by endothelial cells and bound platelets during thrombus formation (Flaumenhaft, 2013).

Several lines of evidence have raced the idea that PDI is directly involved in thrombus formation by regulating the activation of proteins required in this process. Interestingly, although this interaction was not fully investigated, TSP-1 was identified as a potential PDI substrate (Bowley et al., 2017). Moreover, the ability of PDI to catalyze the formation of TSP-1-Thrombin–Antithrombin III complex was shown in vitro (Milev and Essex, 1999).

A fine tuning of Peroxiredoxin 1 activity, strictly connected to extracellular hydrogen peroxide (H$_2$O$_2$) levels, was suggested to play a role in wound healing process. H$_2$O$_2$ is normally produced by mammalian cells as result of metabolic processes. In specific conditions, such as wound healing, the amount of produced H$_2$O$_2$ increases considerably, representing a protection against pathogens, but its toxic accumulation must be prevented by enzymes also belonging to the peroxiredoxin family (Schäfer and Werner, 2008). Low levels of H$_2$O$_2$ are essential for propagation of intracellular signaling triggered by growth factor and required for re-epithelization. Peroxiredoxin 1 resulted inactivated at the margin of healing cutaneous wounds in mice to allow wound repair mediated by H$_2$O$_2$ (Woo et al., 2010).

Alpha-enolase (ENO1) is another AMEL-2 interactor, involved in regeneration processes. Indeed, ENO1 is a key glycolytic enzyme that catalyzes the dehydration of 2-phospho-D-glycerate to phosphor-enol-pyruvate. Besides its cytoplasmic localization, ENO1 is exposed on the cell surface where acts as a plasminogen receptor (Miles et al., 1991). When translocated to the cell surface, ENO1 contributes to pericellular plasmin generation that in turn plays a crucial part in degradation of fibrin provisional matrix and other ECM components. The ENO1 increased cell-surface expression was suggested to have an important role also in inflammatory cell invasion (Wygrecka et al., 2009).

Guanine nucleotide-binding protein subunit beta-2-like 1, commonly defined as RACK1, is a WD40 repeat protein that showed a wide variety of cellular interactors involved in determining the physiology of healing wounds. Many other biological partners may be involved in RACK1 dependent regulation of cell migration (Hermanto et al., 2002; Cox et al., 2003; Songhai et al., 2008).

Among all potential AMEL-2 targets, we pointed out our attention mainly on TSP-1. This protein was fished out by AMEL-2 both in HUVEC cell lysates and secretomes, as the unique common partner. Moreover, in the HUVEC secretomes fibronectin (FINC) was identified as an AMEL-2 interacting protein. Since fibronectin is a well-known specific target of TSP-1 as also reported by interactome analysis by STRING, we were interested to better analyze this PPI pathway. Indeed, both TSP-1 and FINC are extra-cellular matrix glycoproteins with adhesive domains interacting between each other.

On this basis, we first validated our proteomic results by immunoblotting analysis and then we proved the direct interaction between TSP-1 and AMEL-2 by surface plasmon resonance, measuring a dissociation constant of around 800 nM. This data excluded a potential role of fibronectin as connection between AMEL-2 and TSP-1 interaction, instead giving evidence for the first time of TSP-1 as new specific AMEL-2 partner.

TSP-1 is a multifunctional extra-cellular matrix glycoprotein produced by several cell types implicated in wound repair, such as keratinocytes, fibroblasts, endothelial cells, and macrophages (DiPietro et al., 1996). Thrombospondins (TSPs) are a small group of secreted, modular glycoproteins. TSP-1 is the most considered element of this class, together with TSP-2, and it is found inside and outside the cell as a 450-kDa trimer. TSP-1 is a prototype matricellular protein that can physically interact with a variety of ligands (Sage and Bornstein, 1991), and seems to be caught up in the regulation of several processes in the healing of skin wounds (Kyriakides and MacLauchlan, 2009). Its mechanism of action has not be yet fully elucidated and controversial data are present in literature: for instance, the ability of TSP-1 to serve as an adhesive substratum was reported in TSP-1 assembly by macrophages facilitating the repair process and providing evidence that TSP-1 production is an important component of optimal wound healing (DiPietro et al., 1996).
However, in other cases, TSP-1 supports cell attachment but not spreading and is counter adhesive when added to an adhesive protein, such as fibronectin (Sage and Bornstein, 1991). Moreover, in endothelial cell, numerous investigations have documented that TSP-1 inhibits endothelial cell chemotaxis, adhesion, attachment, and capillary growth in vitro (Murphy-Ullrich and Höök, 1989). Finally, wound healing studies in TSP1-null mice specified a tardy repair, characterized by loosely compacted and disorganized granulation tissue (Agah et al., 2005).

On this basis, the finding of a direct interaction between AMEL-2 and TSP-1 can represent an important result to give a better understanding about the role of AMEL-2 in the complex network of the regeneration process. We can postulate that AMEL-2 interaction with TSP-1 may modulate the recognition between this latter protein and FINC which induces a TSP-1 conformation change related to its stabilization and its incorporation into ECM (Tan and Lawler, 2009). This, in turn, may alter the regeneration process and wound healing. This result open the way to following studies to evaluate the potential mechanism of amelogenins in the wound healing process.

**AUTHOR CONTRIBUTIONS**

AR, MC, AGC, and MM conceived and designed the experiments; ANC, CC, and GA performed the experiments; RR and MM analyzed the data; RR and MM wrote the paper.

**FUNDING**

This work was supported by grants from MIUR ITALY PRIN2015 “Top-down and Bottom-up approach in the development of new bioactive chemical entities inspired on natural products scaffolds” (Project N. 2015MSCKCE_003). The financial support by University of Salerno and DAMOR Farmaceutici s.r.l. is also gratefully acknowledged.

**ACKNOWLEDGMENTS**

Prof Leif Bülow (Department of Pure and Applied Biochemistry, Lund University, Lund, Sweden) is kindly acknowledged for providing AMEL-2. Dr. M. Festa and Prof. M.C. Turco (University of Salerno) are kindly acknowledged for providing HUVEC cells.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2017.00074/full#supplementary-material
and contact with extracellular matrix. Mol. Cell. Biol. 22, 2345–2365. doi: 10.1128/MCB.22.7.2345-2365.2002

Hoang, A. M., Oates, T. W., and Cochran, D. L. (2000). In Vitro wound healing responses to enamel matrix derivative. J. Periodontol. 71, 1270–1277. doi: 10.1902/jop.2000.71.8.1270

Lambrecht, A., Van Troys, M., and Ampe, C. (2004). The actin cytoskeleton in normal and pathological cell motility. Int. J. Biochem. Cell. Biol. 36, 1890–1909. doi: 10.1016/j.biocell.2004.01.024

Laufenburger, D. A., and Horwitz, A. F. (1996). Cell migration: a physically integrated molecular process. Cell 84, 359–369. doi: 10.1006/bibi.1998.0983

Moradian-Oldak, J. (2001). Amelogenins: assembly, processing and control of crystal morphology. Matrix Biol. 20, 293–305. doi: 10.1016/S0945-053X(01)00154-8

Murphy-Ullrich, J. E., and Höök, M. (1989). Thrombospondin modulates focal adhesions in endothelial cells. J. Cell Biol. 109, 1309–1319. doi: 10.1083/jcb.109.3.1309

Raida, M. (2011). Drug target deconvolution by chemical proteomics. Curr. Opin. Chem. Biol. 15, 570–575. doi: 10.1016/j.cbpa.2011.06.016

Resovi, A., Pinessi, D., Chiorino, G., and Taraboletti, G. (2014). Current understanding of the thrombospondin-1 interactome. Matrix Biol. 37, 83–91. doi: 10.1016/j.matbio.2014.01.012

Romanelli, M., Dini, V., Vowden, P., and Ågren, M. S. (2008a). Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: experimental and clinical evidence. Clin. Interv. Aging 3, 263–272. doi: 10.2147/CIA.S1846

Sasaki, S., and Shimokawa, H. (1995). The amelogenin gene. Int. J. Dev. Biol. 39, 127–133.

Schäfer, M., and Werner, S. (2008). Oxidative stress in normal and impaired wound repair. Pharmacol. Res. 58, 165–171. doi: 10.1016/j.phrs.2008.06.004

Salski, A., Kasprzyk, A., Rychli, M., and Kuba, M. (2016). Identification of Trombospondin-1 as Amelogenin Interactor. J. Cell Commun. Signal. 3, 177–187. doi: 10.1083/j.s12079-009-0074-2

Sharma, D., and Bisht, D. (2017a). Role of bacterioferritin and ferritin in M. tuberculosis pathogenesis and drug resistance: a future perspective by interactomic approach. Front. Cell. Infect. Microbiol. 7:240. doi: 10.3389/fcimb.2017.00240

Sharma, D., and Bisht, D. (2017b). Secretory proteome analysis of streptomycin-resistant Mycobacterium tuberculosis clinical isolates. SLAS Discov. 1, 1247255521698428. doi: 10.1177/1247255521698428

Sharma, D., Lata, M., Faheem, M., Khan, A. U., Joshi, B., Venkatesan, K., et al. (2016a). M. tuberculosis ferritin (Rv3841): potential involvement in Amikacin (AK) and Kanamycin (KM) resistance. Biochem. Biophys. Res. Commun. 478, 908–912. doi: 10.1016/j.bbrc.2016.08.049

Sharma, D., Lata, M., Singh, R., Deo, N., Venkatesan, K., and Bisht, D. (2016b). Cytoprotective profiling of aminglycocsides-resistant Mycobacterium tuberculosis clinical isolates using MALDI-TOF/MS. Front. Microbiol. 7:1816. doi: 10.3389/fmicb.2016.01816

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.